Mode
Text Size
Log in / Sign up
N/A N=146 Randomized Quadruple-blind Treatment

Antibiotic Prophylaxis in Orthopaedic Traumatology

Fractures, Closed · Wounds and Injuries

Enrolled (actual)
146
Serious AEs
27.4%
Results posted
Jun 2015
Primary outcome: Primary: Number of Participants With Total Wound Infections — 4; 9 participants — p==0.12

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
cefazolin (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Missouri-Columbia
Primary completion
Jan 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Total Wound Infections
4; 9 =0.12

Summary

It has been established that providing antibiotic prophylaxis after closed fracture fixation with implants or prosthetic devices has beneficial effects. However, the optimal duration of antibiotic prophylaxis after orthopaedic trauma surgery is not well-defined. Most studies comparing single-dose prophylaxis with multiple-dose prophylaxis have not shown beneficial effects of additional doses. Our proposed study is intended to further define the appropriate duration of antibiotic (cefazolin) administration for surgical prophylaxis in the treatment of closed fractures. We will randomly assigned patients into two groups, hopefully differentiated only by the duration of antibiotic administration (single dose vs. 24 hours). We will follow these patients until fracture healing and determine if there is a difference in the incidence of infection.

Eligibility Criteria

Inclusion Criteria

  • Patients 18 years or older;
  • Scheduled for primary osteosynthesis or placement of a prosthetic device in the treatment of closed limb fractures;
  • Ability to give informed consent.

Exclusion Criteria

  • Known hypersensitivity to cephalosporins;
  • Antimicrobial use or symptoms of infection in the week before surgery;
  • Pregnancy;
  • Immunosuppressive treatment;
  • Inability to give informed consent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00610987). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search